134 related articles for article (PubMed ID: 16312222)
1. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas.
Kringen P; Bergamaschi A; Due EU; Wang Y; Tagliabue E; Nesland JM; Nehman A; Tönisson N; Børresen-Dale AL
Biotechniques; 2005 Nov; 39(5):755-61. PubMed ID: 16312222
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene.
Tõnisson N; Zernant J; Kurg A; Pavel H; Slavin G; Roomere H; Meiel A; Hainaut P; Metspalu A
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5503-8. PubMed ID: 11960007
[TBL] [Abstract][Full Text] [Related]
3. Low density DNA microarray for detection of most frequent TP53 missense point mutations.
Rangel-López A; Maldonado-Rodríguez R; Salcedo-Vargas M; Espinosa-Lara JM; Méndez-Tenorio A; Beattie KL
BMC Biotechnol; 2005 Feb; 5():8. PubMed ID: 15713227
[TBL] [Abstract][Full Text] [Related]
4. High resolution melting for mutation scanning of TP53 exons 5-8.
Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
[TBL] [Abstract][Full Text] [Related]
5. APEX disease gene resequencing: mutations in exon 7 of the p53 tumor suppressor gene.
Shumaker JM; Tollet JJ; Filbin KJ; Montague-Smith MP; Pirrung MC
Bioorg Med Chem; 2001 Sep; 9(9):2269-78. PubMed ID: 11553465
[TBL] [Abstract][Full Text] [Related]
6. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
7. Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE).
Sørlie T; Johnsen H; Vu P; Lind GE; Lothe R; Børresen-Dale AL
Methods Mol Biol; 2014; 1105():315-24. PubMed ID: 24623239
[TBL] [Abstract][Full Text] [Related]
8. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
9. Genotyping microarray (gene chip) for the ABCR (ABCA4) gene.
Jaakson K; Zernant J; Külm M; Hutchinson A; Tonisson N; Glavac D; Ravnik-Glavac M; Hawlina M; Meltzer MR; Caruso RC; Testa F; Maugeri A; Hoyng CB; Gouras P; Simonelli F; Lewis RA; Lupski JR; Cremers FP; Allikmets R
Hum Mutat; 2003 Nov; 22(5):395-403. PubMed ID: 14517951
[TBL] [Abstract][Full Text] [Related]
10. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis.
Wen WH; Bernstein L; Lescallett J; Beazer-Barclay Y; Sullivan-Halley J; White M; Press MF
Cancer Res; 2000 May; 60(10):2716-22. PubMed ID: 10825146
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
[TBL] [Abstract][Full Text] [Related]
12. [Application of oligonucleotide microarray primer extension to detection of p53 single nucleotide polymorphisms].
Wu QH; Ma WL; Zhang B; Guo QY; Li L; Zheng WL
Ai Zheng; 2005 Jul; 24(7):898-902. PubMed ID: 16004824
[TBL] [Abstract][Full Text] [Related]
13. Unravelling genetic data by arrayed primer extension.
Tõnisson N; Kurg A; Kaasik K; Lõhmussaar E; Metspalu A
Clin Chem Lab Med; 2000 Feb; 38(2):165-70. PubMed ID: 10834405
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
[TBL] [Abstract][Full Text] [Related]
15. Arrayed primer extension reaction for genotyping on oligonucleotide microarray.
Pullat J; Metspalu A
Methods Mol Biol; 2008; 444():161-7. PubMed ID: 18425479
[TBL] [Abstract][Full Text] [Related]
16. Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology.
Kurg A; Tõnisson N; Georgiou I; Shumaker J; Tollett J; Metspalu A
Genet Test; 2000; 4(1):1-7. PubMed ID: 10794354
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection.
Andersen TI; Børresen AL
Diagn Mol Pathol; 1995 Sep; 4(3):203-11. PubMed ID: 7493140
[TBL] [Abstract][Full Text] [Related]
18. Oligonucleotide probe array for p53 gene alteration analysis in DNA from formalin-fixed paraffin-embedded breast cancer tissues.
Lumachi F; Marino F; Varotto S; Basso U
Ann N Y Acad Sci; 2009 Sep; 1175():89-92. PubMed ID: 19796081
[TBL] [Abstract][Full Text] [Related]
19. Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction.
Bjørheim J; Lystad S; Lindblom A; Kressner U; Westring S; Wahlberg S; Lindmark G; Gaudernack G; Ekstrøm P; Røe J; Thilly WG; Børresen-Dale AL
Mutat Res; 1998 Jul; 403(1-2):103-12. PubMed ID: 9726011
[TBL] [Abstract][Full Text] [Related]
20. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.
Langerød A; Bukholm IR; Bregård A; Lønning PE; Andersen TI; Rognum TO; Meling GI; Lothe RA; Børresen-Dale AL
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1684-8. PubMed ID: 12496062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
